Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach

Critical Care Medicine

Volumn 28, Issue 9 SUPPL., 2000, Pages

  Thijs, L G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antithrombin III; Coagulation; Coagulation inhibitor; Protein C; Sepsis; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN III; PROTEIN C; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMPLEX FORMATION; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; REVIEW; SEPSIS; THROMBIN TIME; TREATMENT OUTCOME;

EID: 0033820257     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200009001-00015     Document Type: Review

References (75)

1. Septic shock in humans
2. Role of cytokines in sepsis
3. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
4. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group
5. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
6. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT Study Group
7. New therapies in sepsis
8. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
9. Antithrombin: Its physiologic importance and role in DIC
10. Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor
11. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor
12. Thrombogenicity of the injured vessel wall, role of antithrombin and heparin
13. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway
14. Characterization of the inhibition of tissue factor in serum
15. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
16. The effect of leukocyte elastase on tissue factor pathway inhibitor
17. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
18. Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction
19. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
20. Time course of hemostatic abnormalities in sepsis and its relation to outcome
21. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies
22. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation
23. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
24. Coagulation, fibrinolysis, and kallikrein systems in sepsis: Relation to outcome
25. Protein C, protein S and C4b-binding protein in severe infection and septic shock
26. Activation of the protein C pathway in acute sepsis
27. Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells
28. Alterations in coagulation and fibrinolysis during sepsis
29. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease
30. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium
31. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor dependent coagulation pathway
32. Antithrombin III: Protection against death after injection of thromboplastin
33. Antithrombin III in animal models of sepsis and organ failure
34. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
35. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
36. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not thrombin-dependent prostacyclin production in human endothelial cells
37. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats
38. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III
39. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats
40. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin
41. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion
42. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
43. C4b-binding protein exacerbates the host response to Escherichia coli
44. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
45. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses
46. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide
47. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
48. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats
49. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction
50. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
51. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock
52. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
53. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
54. The coagulant-inflammatory axis in the baboon response to E. coli: Effects of tissue factor pathway inhibitor on hemostatic balance, the cytokine network and the release of apoptosis marker sFas
55. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
56. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli
57. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
58. Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate
59. Treatment of purpura fulminans in meningococcemia with protein C concentrate
60. Severe acquired protein C deficiency in purpura fulmimans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
61. Use of protein-C concentrate, heparin, and haemo-diafiltration in meningococcus-induced purpura fulminans
62. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis
63. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis
64. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure
65. Therapeutic use of antithrombin concentrate in sepsis
66. Antithrombin III transfusion in disseminated intravascular coagulation
67. Substitution of antithrombin III in shock and DIC: A randomized study
68. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation
69. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
70. Antithrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized placebo-controlled, double-blind trials with antithrombin III in severe sepsis
71. Prospective double-blind, placebo-controlled trial of AT III substitution in sepsis
72. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
73. Effect of antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction
74. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis